Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 116 articles:
HTML format



Single Articles


    June 2022
  1. MATSUMURA K, Yamamura K, Oda E, Akahoshi S, et al
    Successful Treatment of Intrahepatic Cholangiocarcinoma With Liver/Lung Metastasis and Peritoneal Dissemination After Liver Resection.
    Anticancer Res. 2022;42:3209-3215.
    PubMed     Abstract available


  2. HIDAKA M, Hara T, Soyama A, Sasaki R, et al
    The Outcome of Conversion Liver Resection Surgery by Lenvatinib Treatment: A Single Center Experience.
    Anticancer Res. 2022;42:3049-3054.
    PubMed     Abstract available


    May 2022
  3. HSIEH CH, Yeh CT, Huang YH, Lai MW, et al
    Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
    Anticancer Res. 2022;42:2479-2486.
    PubMed     Abstract available


  4. KUMAMOTO T, Matsuyama R, Takeda K, Sawada YU, et al
    Surgical Indications for Huge Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:2573-2581.
    PubMed     Abstract available


  5. YANG CJ, Wu MH, Tsai JJ, Hsu FT, et al
    Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
    Anticancer Res. 2022;42:2495-2505.
    PubMed     Abstract available


    April 2022
  6. KUZUYA T, Kawabe N, Hashimoto S, Funasaka K, et al
    Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1905-1910.
    PubMed     Abstract available


  7. HANAKI T, Sunaguchi T, Goto K, Morimoto M, et al
    The Significance of Surgical Intervention for Metasynchronous Liver Metastasis in Gastric Cancer: A Single-centre Analysis.
    Anticancer Res. 2022;42:2177-2184.
    PubMed     Abstract available


  8. TOMITA K, Chiba N, Ochiai S, Gunji T, et al
    Prognostic Impact of N2 of the Primary Tumour in Surgical Resection for Colorectal Liver Metastases.
    Anticancer Res. 2022;42:1997-2001.
    PubMed     Abstract available


    March 2022
  9. KOMATSU S, Yano Y, Fujishima Y, Ishida J, et al
    Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2022;42:1403-1412.
    PubMed     Abstract available


  10. HAMAYA S, Fujihara S, Iwama H, Fujita K, et al
    Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Anticancer Res. 2022;42:1263-1275.
    PubMed     Abstract available


  11. MATSUMURA K, Yamamura K, Miyamoto H, Hara Y, et al
    Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer Res. 2022;42:1645-1651.
    PubMed     Abstract available


  12. BARAK V, Kalickman I, Pe'er J
    sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
    Anticancer Res. 2022;42:1447-1453.
    PubMed     Abstract available


  13. TASHIRO Y, Aoki T, Hirai T, Koizumi T, et al
    Indocyanine Green Labeling of Tumors in the Liver Recurring After Radiofrequency Ablation Enables Complete Resection by Fluorescence-guided Surgery.
    Anticancer Res. 2022;42:1345-1350.
    PubMed     Abstract available


    February 2022
  14. ICHIDA A, Akamatsu N, Nagata R, Mihara Y, et al
    Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
    Anticancer Res. 2022;42:1161-1167.
    PubMed     Abstract available


  15. ABE K, Maeda-Minami A, Ishizu T, Iwata S, et al
    Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma.
    Anticancer Res. 2022;42:1043-1050.
    PubMed     Abstract available


  16. FUJITA N, Handa A, Park JM
    Peritumoral Hyperintensity at Hepatobiliary Phase Gadoxetic Acid-enhanced MRI in Hepatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:911-917.
    PubMed     Abstract available


  17. JANG WI, Kim MS, Jeong JH, Kim W, et al
    Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort Study.
    Anticancer Res. 2022;42:867-876.
    PubMed     Abstract available


  18. ZIOGAS IA, Schmitz R, Moris D, Vatsaas CJ, et al
    The Role of Surgery for Pancreatic Neuroendocrine Tumors.
    Anticancer Res. 2022;42:629-639.
    PubMed     Abstract available


    January 2022
  19. YAMAMURA K, Beppu T, Miyata T, Okabe H, et al
    Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy.
    Anticancer Res. 2022;42:35-44.
    PubMed     Abstract available


  20. AURELLO P, Minervini A, Pace M, D'Angelo F, et al
    The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review.
    Anticancer Res. 2022;42:25-33.
    PubMed     Abstract available


  21. INOUE KI, Yamagishi H, Jojima T, Inoue T, et al
    Development of Non-alcoholic Steatohepatitis and Nodular Regenerative Hyperplasia in C57BL/6J Mice Fed a Fructose-containing Western Diet.
    Anticancer Res. 2022;42:609-617.
    PubMed     Abstract available


  22. JUNG JY, Koh SA, Lee KH, Kim JR, et al
    14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion via Matrix Metalloproteinase-1 Regulation in Human Gastric Cancer.
    Anticancer Res. 2022;42:519-530.
    PubMed     Abstract available


  23. MIZUOCHI S, Akiba J, Kondo R, Kusano H, et al
    Clinicopathological Analysis of Non-B Non-C Hepatocellular Carcinoma Focusing on Cellular Proliferation.
    Anticancer Res. 2022;42:449-457.
    PubMed     Abstract available


  24. HARIMOTO N, Itoh S, Yamanaka T, Hagiwara K, et al
    Mac-2 Binding Protein Glycosylation Isomer as a Prognostic Marker for Hepatocellular Carcinoma With Sustained Virological Response.
    Anticancer Res. 2022;42:245-251.
    PubMed     Abstract available


  25. SHIMOZATO N, Namisaki T, Okano A, Ohana M, et al
    Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
    Anticancer Res. 2022;42:173-183.
    PubMed     Abstract available


    November 2021
  26. IMAI N, Yokoyama S, Yamamoto K, Ito T, et al
    Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes.
    Anticancer Res. 2021;41:5817-5820.
    PubMed     Abstract available


  27. OMIYA S, Komatsu S, Kido M, Kuramitsu K, et al
    Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:5775-5783.
    PubMed     Abstract available


  28. ADACHI Y, Yamamura K, Yumoto S, Higashi T, et al
    Far-advanced Colorectal Liver Metastases Successfully Managed With Modified ALPPS and Radiofrequency Ablation in Combination With Chemotherapy.
    Anticancer Res. 2021;41:5855-5861.
    PubMed     Abstract available


  29. FURUKAWA K, Onda S, Taniai T, Hamura R, et al
    Risk Factors and Overcoming Strategies of Surgical Site Infection After Hepatectomy for Colorectal Liver Metastases.
    Anticancer Res. 2021;41:5651-5656.
    PubMed     Abstract available


  30. MASATSUNE S, Kimura K, Kashiwagi S, En W, et al
    Impact of Intraoperative Blood Loss and Blood Transfusion on the Prognosis of Colorectal Liver Metastasis Following Curative Resection.
    Anticancer Res. 2021;41:5617-5623.
    PubMed     Abstract available


  31. TAGO T, Katsumata K, Udou R, Kasahara K, et al
    Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases.
    Anticancer Res. 2021;41:5539-5547.
    PubMed     Abstract available


  32. TSOCHANTARIDIS I, Voulgaridou GP, Giatromanolaki A, Koukourakis MI, et al
    Profiling of Aldehyde Dehydrogenase Isoforms in In Vitro Formed Tumorspheres.
    Anticancer Res. 2021;41:5481-5488.
    PubMed     Abstract available


    October 2021
  33. ODA E, Yamamura K, Hara Y, Matsumura K, et al
    Intrahepatic Cholangiocarcinoma Coexisting With Multiple Bile Duct Adenoma Treated as Liver Metastasis from a Pancreatic Neuroendocrine Tumor.
    Anticancer Res. 2021;41:5249-5254.
    PubMed     Abstract available


  34. KIM M, Kim HC, Chung JW
    Chemoembolization for Hepatocellular Carcinoma in Patients With Inferior Vena Caval/Right Atrial Tumor Thrombi Without Hepatic Vein Invasion.
    Anticancer Res. 2021;41:5241-5247.
    PubMed     Abstract available


  35. MOON H, Park H, Ro SW
    c-Myc-driven Hepatocarcinogenesis.
    Anticancer Res. 2021;41:4937-4946.
    PubMed     Abstract available


    September 2021
  36. KOMATSU S, Yano Y, Kido M, Kuramitsu K, et al
    Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4555-4562.
    PubMed     Abstract available


  37. OKAMOTO H, Shiba S, Iino H, Sudoh M, et al
    Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
    Anticancer Res. 2021;41:4505-4513.
    PubMed     Abstract available


  38. TSUNEMATSU M, Onda S, Yanagaki M, Okui N, et al
    How to Perform Curative Laparoscopic Hepatectomy for Intraoperatively Unidentified Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:4411-4416.
    PubMed     Abstract available


  39. TOKUDA K, Morine Y, Miyazaki K, Yamada S, et al
    Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:4637-4644.
    PubMed     Abstract available


    August 2021
  40. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available


  41. OURA K, Aoki T, Tashiro Y, Matsuda K, et al
    Indocyanine Green Fluorescence Image-guided Laparoscopic Hepatectomy Enabled Resection of a Tumor Invisible With Ultrasonography.
    Anticancer Res. 2021;41:3867-3869.
    PubMed     Abstract available


    July 2021
  42. KUBO H, Ikoma H, Yamamoto Y, Morimura R, et al
    Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram.
    Anticancer Res. 2021;41:3657-3665.
    PubMed     Abstract available


  43. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available


    June 2021
  44. AU KY, Chan KK, Lo RC
    A Clinicopathological Study of Young-onset Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2933-2944.
    PubMed     Abstract available


    May 2021
  45. YAMAMURA K, Beppu T, Oda E, Sato N, et al
    Hepatic Inflammatory Pseudotumor Mimicking Malignant Tumor With Rare Onset of Intra-abdominal Hemorrhage.
    Anticancer Res. 2021;41:2727-2732.
    PubMed     Abstract available


  46. KIM HC, Choi JW, Lee M, Kim YJ, et al
    Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response.
    Anticancer Res. 2021;41:2625-2635.
    PubMed     Abstract available


  47. YAMAMOTO T, Imai N, Yamamoto K, Ito T, et al
    Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.
    Anticancer Res. 2021;41:2569-2573.
    PubMed     Abstract available


  48. ISHIGAMI I, Shuwari N, Kaminade T, Mizuguchi H, et al
    A TGFbeta Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFbeta-independent Manner.
    Anticancer Res. 2021;41:2431-2440.
    PubMed     Abstract available


  49. SHIBUTANI M, Kimura K, Kashiwagi S, Wang EN, et al
    Elevated Postoperative Levels of Serum C-reactive Protein Are Associated With Shorter Long-term Survival After Resection of Colorectal Liver Metastases, Regardless of the Occurrence of Infectious Complications.
    Anticancer Res. 2021;41:2605-2610.
    PubMed     Abstract available


  50. NISHIKAWA H, Fukunishi S, Asai A, Nishiguchi S, et al
    Obesity and Liver Cancer in Japan: A Comprehensive Review.
    Anticancer Res. 2021;41:2227-2237.
    PubMed     Abstract available


    April 2021
  51. MAESAKA K, Sakamori R, Yamada R, Tahata Y, et al
    Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2187-2192.
    PubMed     Abstract available


  52. FURUKAWA K, Haruki K, Yasuda J, Onda S, et al
    Strategies to Perform Curative Laparoscopic Repeat Hepatectomy for Recurrent Liver Tumors After Open Right Lobectomy.
    Anticancer Res. 2021;41:2171-2175.
    PubMed     Abstract available


  53. SASAKI R, Fukushima M, Haraguchi M, Miuma S, et al
    Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
    Anticancer Res. 2021;41:2025-2032.
    PubMed     Abstract available


  54. SHAO C, Shao PP, Chen WT, Lin CC, et al
    Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients.
    Anticancer Res. 2021;41:2007-2016.
    PubMed     Abstract available


  55. YASUHARA Y, Komatsu S, Kuramitsu K, Kido M, et al
    Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:1975-1983.
    PubMed     Abstract available


  56. LEE GW, Hur W, Kim JH, Park DJ, et al
    Nardostachys jatamansi Root Extract Attenuates Tumor Progression in Hepatocellular Carcinoma via Inhibition of ERK/STAT3 Pathways.
    Anticancer Res. 2021;41:1883-1893.
    PubMed     Abstract available


  57. NISHINO H, Okuno M, Seo S, Toda R, et al
    Sinusoidal Obstruction Syndrome Promotes Liver Metastatic Seeding of Colorectal Cancer Cells in a Rat Model.
    Anticancer Res. 2021;41:1803-1810.
    PubMed     Abstract available


  58. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available


    March 2021
  59. PERL RM, Portugall J, Hinterleitner C, Hinterleitner M, et al
    Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Anticancer Res. 2021;41:1451-1458.
    PubMed     Abstract available


  60. PARK SY, Seo YR, Ko MJ, Lee JH, et al
    Targeting CALM2 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Suppressing E2F5-mediated Cell Cycle Progression.
    Anticancer Res. 2021;41:1315-1325.
    PubMed     Abstract available


  61. AKIBA J, Yoshida T, Sadashima E, Murata K, et al
    The Expression of PEDF and its Putative Receptors in Hepatocellular Carcinoma and Background Liver Tissue.
    Anticancer Res. 2021;41:1203-1212.
    PubMed     Abstract available


  62. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
    Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
    Anticancer Res. 2021;41:1571-1577.
    PubMed     Abstract available


  63. HIROSE Y, Sakata J, Kobayashi T, Miura K, et al
    NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:1563-1570.
    PubMed     Abstract available


    February 2021
  64. LEE HP, Tsai KW, Lee CC
    Prognostic Influence of Cytoplasmic/Nuclear Hepatoma-derived Growth Factor in Head and Neck Cancer.
    Anticancer Res. 2021;41:803-810.
    PubMed     Abstract available


  65. OSAWA M, Matsuda Y, Kinoshita Y, Wakai T, et al
    Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
    Anticancer Res. 2021;41:645-660.
    PubMed     Abstract available


  66. KABADI SM, Byfield SD, LE L, Olufade T, et al
    Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Anticancer Res. 2021;41:927-936.
    PubMed     Abstract available


    January 2021
  67. SAITO R, Amemiya H, Hosomura N, Kawaida H, et al
    Stroke Volume Variation Monitoring to Minimize Blood Loss in Hepatocellular Carcinoma Resection.
    Anticancer Res. 2021;41:409-415.
    PubMed     Abstract available


  68. AMEMIYA H, Matsuda M, Saito R, Hosomura N, et al
    Impact of Insulin Treatment on Prognosis of non-B non-C Hepatocellular Carcinoma After Hepatectomy.
    Anticancer Res. 2021;41:317-326.
    PubMed     Abstract available


  69. FABRITIUS MP, Hartmann F, Seidensticker R, Pech M, et al
    Liver Function Changes After Technetium-99m-Macroaggregated Albumin Administration and Their Predictive Value Regarding Hepatotoxicity in Patients Undergoing Yttrium-90-Radioembolization.
    Anticancer Res. 2021;41:437-444.
    PubMed     Abstract available


  70. KIM EJ, Kim M, Seo S, Kim MJ, et al
    Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
    Anticancer Res. 2021;41:391-402.
    PubMed     Abstract available


    December 2020
  71. CHEN SY, Chao CN, Huang HY, Fang CY, et al
    Flavopereirine Inhibits Hepatocellular Carcinoma Cell Growth by Inducing Cell-cycle Arrest, Apoptosis, and Autophagy-related Protein Expression.
    Anticancer Res. 2020;40:6907-6914.
    PubMed     Abstract available


  72. LLUCH P, Segarra G, Tosca J, Navarro L, et al
    Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients.
    Anticancer Res. 2020;40:6853-6861.
    PubMed     Abstract available


  73. ABREU P, Ferreira R, Mineli V, Ribeiro MA, et al
    Alternative Biomarkers to Predict Tumor Biology in Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:6573-6784.
    PubMed     Abstract available


  74. SATO N, Yamamura K, Oda E, Akahoshi S, et al
    Cholangiolocarcinoma With Multiple Recurrences Successfully Treated With Repeated Liver Resection and Radiofrequency Ablation.
    Anticancer Res. 2020;40:7147-7153.
    PubMed     Abstract available


  75. YAMAMOTO J, Sugisawa N, Hamada K, Nishino H, et al
    A Universal Gelfoam 3-D Histoculture Method to Establish Patient-derived Cancer Cells (3D-PDCC) Without Fibroblasts from Patient-derived Xenografts.
    Anticancer Res. 2020;40:6765-6768.
    PubMed     Abstract available


  76. NAKAGAWA N, Tanaka K, Sonohara F, Kandimalla R, et al
    Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue.
    Anticancer Res. 2020;40:6665-6676.
    PubMed     Abstract available


  77. PALEK R, Rosendorf J, Maleckova A, Vistejnova L, et al
    Influence of Mesenchymal Stem Cell Administration on The Outcome of Partial Liver Resection in a Porcine Model of Sinusoidal Obstruction Syndrome.
    Anticancer Res. 2020;40:6817-6833.
    PubMed     Abstract available


    November 2020
  78. YAMAMURA K, Beppu T, Kinoshita K, Oda E, et al
    Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report.
    Anticancer Res. 2020;40:6465-6471.
    PubMed     Abstract available


  79. DAHLQUIST KJV, Voth LC, Fee AJ, Stoeckman AK, et al
    An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:6075-6081.
    PubMed     Abstract available


  80. TOMIOKA K, Aoki T, Matsuda K, Fujimori A, et al
    Usefulness of a Transumbilical Incision for Organ Removal in Laparoscopic Hepatectomy.
    Anticancer Res. 2020;40:6545-6550.
    PubMed     Abstract available


  81. AHMED A, Halama N
    Tertiary Lymphoid Structures in Colorectal Cancer Liver Metastases: Association With Immunological and Clinical Parameters and Chemotherapy Response.
    Anticancer Res. 2020;40:6367-6373.
    PubMed     Abstract available


    October 2020
  82. YAMAMURA K, Beppu T, Sato N, Kinoshita K, et al
    Complete Removal of Adrenal Metastasis in Hepatocellular Carcinoma Using Indocyanine Green Fluorescent Imaging.
    Anticancer Res. 2020;40:5823-5828.
    PubMed     Abstract available


  83. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
    A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Anticancer Res. 2020;40:5393-5397.
    PubMed     Abstract available


    September 2020
  84. NARITA R, Kotoh K, Yoneda A, Motomura M, et al
    Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:5271-5276.
    PubMed     Abstract available


  85. GABATA R, Harada K, Mizutani Y, Ouchi H, et al
    Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against beta-Catenin-activated Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:5211-5219.
    PubMed     Abstract available


  86. NAKURA M, Miyashita T, Yamamoto Y, Takada S, et al
    Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome.
    Anticancer Res. 2020;40:5171-5180.
    PubMed     Abstract available


  87. WU TK, Chen CH, Lee WT, Su TF, et al
    Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling.
    Anticancer Res. 2020;40:5059-5069.
    PubMed     Abstract available


  88. OWADA S, Endo H, Okada C, Yoshida K, et al
    Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer.
    Anticancer Res. 2020;40:5071-5079.
    PubMed     Abstract available


    August 2020
  89. GOTO Y, Hisaka T, Sakai H, Takagi K, et al
    Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
    Anticancer Res. 2020;40:4773-4777.
    PubMed     Abstract available


  90. KOJIMA S, Hisaka T, Midorikawa R, Naito Y, et al
    Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2020;40:4749-4754.
    PubMed     Abstract available


  91. HAN YH, Li WL, Jin MH, Jin YH, et al
    Peroxiredoxin II Inhibits Alcohol-induced Apoptosis in L02 Hepatocytes Through AKT/beta-Catenin Signaling Pathway.
    Anticancer Res. 2020;40:4491-4504.
    PubMed     Abstract available


  92. KWON JH, Yoo SH, Nam SW, Lee YJ, et al
    Diagnostic Role of Contrast-enhanced Ultrasound in the Discrimination of Malignant Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4351-4363.
    PubMed     Abstract available


  93. HARIMOTO N, Araki K, Ishii N, Muranushi R, et al
    Predictors of Postoperative Ascites After Hepatic Resection in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4343-4349.
    PubMed     Abstract available


  94. HEINZE C, Omari J, Damm R, Hass P, et al
    Interstitial Brachytherapy for Limited (<4 cm) and Large (>/=4 cm) Hepatic Metastases from Rare and Less Common Cancers.
    Anticancer Res. 2020;40:4281-4289.
    PubMed     Abstract available


  95. YUE CH, Chen CH, Lee WT, Su TF, et al
    Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway.
    Anticancer Res. 2020;40:4513-4522.
    PubMed     Abstract available


  96. HISAKA T, Sakai H, Sato T, Goto Y, et al
    Quercetin Suppresses Proliferation of Liver Cancer Cell Lines In Vitro.
    Anticancer Res. 2020;40:4695-4700.
    PubMed     Abstract available


    July 2020
  97. KIM HC, Joo I, Lee M, Kim YJ, et al
    Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4191-4198.
    PubMed     Abstract available


  98. AMANUMA M, Nagai H, Igarashi Y
    Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption.
    Anticancer Res. 2020;40:4173-4182.
    PubMed     Abstract available


  99. NAKAMURA M, Ueno M, Hayami S, Kawai M, et al
    Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Anticancer Res. 2020;40:4123-4129.
    PubMed     Abstract available


  100. SHIOGA T, Kondo R, Ogasawara S, Akiba J, et al
    Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4105-4113.
    PubMed     Abstract available


  101. SAKURAOKA Y, Kubota K, Tanaka G, Shimizu T, et al
    Features of Hepatocellular Carcinoma With Micro Hepatic Vein Invasion and their Correlation With Hepatitis B and C Virus.
    Anticancer Res. 2020;40:3983-3990.
    PubMed     Abstract available


  102. MORIGUCHI M, Aramaki T, Sato R, Iwai K, et al
    Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:3953-3960.
    PubMed     Abstract available


  103. IGUCHI T, Sugimachi K, Mano Y, Motomura T, et al
    Prognostic Impact of Geriatric Nutritional Risk Index in Patients With Synchronous Colorectal Liver Metastasis.
    Anticancer Res. 2020;40:4165-4171.
    PubMed     Abstract available


  104. TASHIRO Y, Aoki T, Hirai T, Koizumi T, et al
    Pathological Validity of Using Near-infrared Fluorescence Imaging for Securing Surgical Margins During Liver Resection.
    Anticancer Res. 2020;40:3873-3882.
    PubMed     Abstract available


  105. XIE DP, Gong YX, Jin YH, Ren CX, et al
    Anti-tumor Properties of Picrasma quassioides Extracts in H-Ras(G12V) Liver Cancer Are Mediated Through ROS-dependent Mitochondrial Dysfunction.
    Anticancer Res. 2020;40:3819-3830.
    PubMed     Abstract available


    June 2020
  106. MIYATA T, Takamura H, Kin R, Nishiki H, et al
    Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
    Anticancer Res. 2020;40:3361-3370.
    PubMed     Abstract available


  107. BAE KB, Kim SH, Kang MS, Kim DH, et al
    An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics.
    Anticancer Res. 2020;40:3297-3306.
    PubMed     Abstract available


    May 2020
  108. KAIDA T, Beppu T, Hayashi H, Imai K, et al
    Inflammatory Liver Tumor Caused by Fasciola hepatica Mimicking Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2020;40:2795-2800.
    PubMed     Abstract available


  109. LIM SC, Parajuli KR, Han SI
    Role of Death Receptors-associated Lipid Rafts in Oxaliplatin-induced Death Mode Regulation of HepG2 Cells.
    Anticancer Res. 2020;40:2573-2582.
    PubMed     Abstract available


    April 2020
  110. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2020;40:2283-2290.
    PubMed     Abstract available


  111. LIU LI, Ahn E, Studeman K, Campbell K, et al
    Primary Hepatic Carcinosarcoma Composed of Hepatocellular Carcinoma, Cholangiocarcinoma, Osteosarcoma and Rhabdomyosarcoma With Poor Prognosis.
    Anticancer Res. 2020;40:2225-2229.
    PubMed     Abstract available


  112. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:2089-2093.
    PubMed     Abstract available


  113. JELSKI W, Piechota J, Orywal K, Mroczko B, et al
    The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy.
    Anticancer Res. 2020;40:1997-2001.
    PubMed     Abstract available


  114. LEE J, Seo G, Hur W, Yoon SK, et al
    SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
    Anticancer Res. 2020;40:2033-2042.
    PubMed     Abstract available


    March 2020
  115. ZARLING L, Emamekhoo H, Bhutani G, Ziemlewicz T, et al
    Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
    Anticancer Res. 2020;40:1527-1534.
    PubMed     Abstract available


  116. PALKOVICS A, Vereczkei A, Fincsur A, Kiss I, et al
    Short- and Long-term Histological Changes in Liver Parenchyma After Different Resection Methods and Their Potential Role in Treatment of Colorectal Liver Metastasis.
    Anticancer Res. 2020;40:1359-1365.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: